Status:

WITHDRAWN

Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)

Lead Sponsor:

Merck Sharp & Dohme LLC

Conditions:

Dyslipidemia

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The purpose of this study is to test the effect of MK0524A (niacin (+) laropiprant) on lowering bad cholesterol and raising good cholesterol.

Eligibility Criteria

Inclusion

  • Patients 18 years of age or older and on a stable dose of lipid therapy

Exclusion

  • Patients lipid level is outside the recommended range
  • Patients that are HIV positive

Key Trial Info

Start Date :

September 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00664287

Start Date

September 1 2008

Last Update

April 9 2015

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082) | DecenTrialz